|
No records
|
|
155 |
Blom I.M., Campos L.N., El Amine Youcef Ali M., Asyura M.M.A.Z., von Metnitz D.Z., Limann B., Janušonytė E. |
57218125715;57256325100;57257173900;57256325200;57257174000;57257030900;57211896142; |
Youth versus pandemics: the role of future generations in the pandemic treaty |
2021 |
The Lancet Global Health |
9 |
10 |
|
e1361 |
e1362 |
|
2 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85114832726&doi=10.1016%2fS2214-109X%2821%2900307-7&partnerID=40&md5=8425b6166dd6fbd88fa21d99ef4c5772 |
International Federation of Medical Students' Associations, Nørre Allé 14, Copenhagen, 2200, Denmark; University of Amsterdam, Amsterdam, Netherlands; Faculty of Medical Sciences, Universidade de Pernambuco, Recife, Brazil; Faculty of Medicine, University of Constantine 3, Constantine, Algeria; Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Sigmund Freud University Vienna, Vienna, Austria; University of Ghana Medical School, Accra, Ghana; Faculty of Medicine, Vilnius University, Vilnius, Lithuania |
Blom, I.M., International Federation of Medical Students' Associations, Nørre Allé 14, Copenhagen, 2200, Denmark, University of Amsterdam, Amsterdam, Netherlands; Campos, L.N., International Federation of Medical Students' Associations, Nørre Allé 14, Copenhagen, 2200, Denmark, Faculty of Medical Sciences, Universidade de Pernambuco, Recife, Brazil; El Amine Youcef Ali, M., International Federation of Medical Students' Associations, Nørre Allé 14, Copenhagen, 2200, Denmark, Faculty of Medicine, University of Constantine 3, Constantine, Algeria; Asyura, M.M.A.Z., International Federation of Medical Students' Associations, Nørre Allé 14, Copenhagen, 2200, Denmark, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; von Metnitz, D.Z., International Federation of Medical Students' Associations, Nørre Allé 14, Copenhagen, 2200, Denmark, Sigmund Freud University Vienna, Vienna, Austria; Limann, B., International Federation of Medical Students' Associations, Nørre Allé 14, Copenhagen, 2200, Denmark, University of Ghana Medical School, Accra, Ghana; Janušonytė, E., International Federation of Medical Students' Associations, Nørre Allé 14, Copenhagen, 2200, Denmark, Faculty of Medicine, Vilnius University, Vilnius, Lithuania |
[No abstract available] |
|
awareness; government; health care organization; health care policy; human; leadership; Note; pandemic; public health; work environment; adult; disaster planning; female; global health; legislation and jurisprudence; male; organization and management; pandemic; social responsibility; World Health Organization; young adult; Adult; Disaster Planning; Female; Global Health; Humans; Male; Pandemics; Social Responsibility; World Health Organization; Young Adult |
Elsevier Ltd |
2214109X |
|
34331865 |
Note |
Q1 |
7970 |
126 |
|
|
|
156 |
Yoanita R., Gunardi H., Rohsiswatmo R., Setyanto D.B. |
57257403000;56510252700;55533574600;57203009929; |
Effect of tactile–kinesthetic stimulation on growth, neurobehavior and development among preterm neonates |
2021 |
Journal of Bodywork and Movement Therapies |
28 |
|
|
180 |
186 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85114826873&doi=10.1016%2fj.jbmt.2021.06.023&partnerID=40&md5=42e65f10f1f437b31aaa9dd4fdb3559e |
Department of Child Health, Dr. Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Indonesia; Developmental Behavioural & Community Pediatrics Division, Department of Child Health, Dr. Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Indonesia; Neonatology Division, Department of Child Health, Dr. Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Indonesia; Pediatric Respirology Division, Department of Child Health, Dr. Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Indonesia |
Yoanita, R., Department of Child Health, Dr. Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Indonesia; Gunardi, H., Developmental Behavioural & Community Pediatrics Division, Department of Child Health, Dr. Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Indonesia; Rohsiswatmo, R., Neonatology Division, Department of Child Health, Dr. Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Indonesia; Setyanto, D.B., Pediatric Respirology Division, Department of Child Health, Dr. Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Indonesia |
Background: Preterm neonates are at risk of delayed growth and development. Hence, early tactile–kinesthetic stimulation (TKS) is required to improve their growth and development. Objective: To evaluate the effect of TKS on growth, neurobehavior and development among preterm neonates. Method: An interventional study was conducted from August 2015 to July 2017 in the neonatal unit of Dr. Cipto Mangunkusumo Hospital. Preterm neonates were recruited via random sampling and divided into two groups (the intervention group and control group). TKS was performed for 15 min, three times a day, for 10 days. The anthropometric measurements, neurobehavior (Dubowitz score) and development (Capute Scale score) of neonates in both groups were assessed. Results: There were 126 preterm neonates (n = 63 in each group). During the 10-day TKS period, the intervention group had a significant increment in weight and length compared to the control group (p < 0.05) at 11–14 days, at term and 3 months. Moreover, increased tone, reflexes, and improvement in behavior based on the Dubowitz score were observed during monitoring. However, the result did not differ significantly (p > 0.05). There was no significant difference in terms of cognitive and language development in both groups (Developmental Quotient of Clinical Linguistic Adaptive Milestone Scale, Developmental Quotient of Clinical Adaptive Test and Full Scale Developmental Quotient scores, p > 0.05). Conclusion: TKS was significantly effective in promoting growth, particularly weight and length, among preterm neonates. However, it did not significantly influence neurobehavior and development at 3 months of chronological age. © 2021 Elsevier Ltd |
Growth; Infant behavior; Infant development; Preterm infants; Tactile perception |
human; kinesthesia; newborn; prematurity; touch; Humans; Infant, Newborn; Infant, Premature; Kinesthesis; Touch |
Churchill Livingstone |
13608592 |
|
34776139 |
Article |
Q1 |
467 |
10672 |
|
|
|
157 |
Meilia P.D.I., Herkutanto, Atmadja D.S., Cordner S., Eriksson A., Kubat B., Kumar A., Payne-James J.J., Rubanzana W.G., Uhrenholt L., Freeman M.D., Zeegers M.P. |
57204065074;57204069374;6507824506;7005870991;7202802446;6602085186;57202849040;7005419201;56514032500;14061357600;34769701500;7003691618; |
The PERFORM-P (Principles of Evidence-based Reporting in FORensic Medicine-Pathology version) |
2021 |
Forensic Science International |
327 |
|
110962 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85114050611&doi=10.1016%2fj.forsciint.2021.110962&partnerID=40&md5=2f9ffc7c51b3342895994d7c7de9fde4 |
Care and Public Health Research Institute (CAPHRI), Maastricht University Medical Center+, Maastricht, Netherlands; Department of Forensic Medicine and Medicolegal Studies, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; The Victorian Institute of Forensic Medicine, Melbourne, Victoria, Australia; Dept of Community Medicine and Rehabilitation/Forensic Medicine, Umeå University, Umeå, Sweden; Faculty of Health, Medicine and Life Science, Maastricht University, Maastricht, Netherlands; Forensic Medicine and Toxicology, All India Institute of Medical SciencesNew Delhi, India; William Harvey Research Institute, Queen Mary University of London, London, UK, United Kingdom; Department of Epidemiology and Biostatistics, University of Rwanda College of Medicine and Health Sciences, School of Public Health, Kigali, Rwanda; Department of Forensic Medicine, Section of Forensic Pathology, Aarhus University, Aarhus, Denmark |
Meilia, P.D.I., Care and Public Health Research Institute (CAPHRI), Maastricht University Medical Center+, Maastricht, Netherlands; Herkutanto, Department of Forensic Medicine and Medicolegal Studies, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Atmadja, D.S., Department of Forensic Medicine and Medicolegal Studies, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Cordner, S., The Victorian Institute of Forensic Medicine, Melbourne, Victoria, Australia; Eriksson, A., Dept of Community Medicine and Rehabilitation/Forensic Medicine, Umeå University, Umeå, Sweden; Kubat, B., Faculty of Health, Medicine and Life Science, Maastricht University, Maastricht, Netherlands; Kumar, A., Forensic Medicine and Toxicology, All India Institute of Medical SciencesNew Delhi, India; Payne-James, J.J., William Harvey Research Institute, Queen Mary University of London, London, UK, United Kingdom; Rubanzana, W.G., Department of Epidemiology and Biostatistics, University of Rwanda College of Medicine and Health Sciences, School of Public Health, Kigali, Rwanda; Uhrenholt, L., Department of Forensic Medicine, Section of Forensic Pathology, Aarhus University, Aarhus, Denmark; Freeman, M.D., Care and Public Health Research Institute (CAPHRI), Maastricht University Medical Center+, Maastricht, Netherlands; Zeegers, M.P., Care and Public Health Research Institute (CAPHRI), Maastricht University Medical Center+, Maastricht, Netherlands |
Introduction: Most findings of forensic pathology examinations are presented as written reports. There are currently no internationally accepted recommendations for writing forensic pathology reports. Existing recommendations are also varied and reflect the differences in the scope and role of forensic medical services and local settings in which they are to be implemented. The legal fact-finder thus faces wide variation in the quality of forensic pathology reports, which poses a threat to the reliability of legal decision-making. To address this issue, the development of the “PERFORM-P (Principles of Evidence-based Reporting in FORensic Medicine-Pathology version)” was undertaken. The goal of the PERFORM-P is to provide common practice recommendations adaptable to local requirements to promote evidence-based practice (EBP) in forensic pathology. Methods: An international consensus study was conducted in three phases by (1) developing a long-list of items to be considered in the reporting recommendations, (2) conducting a Delphi process (an iterative survey method to transform individual opinions into group consensus) with international forensic pathologists, and (3) designing the PERFORM-P prototype and its accompanying manual. Results: With assistance from 106 forensic pathologists/forensic medical practitioners from 41 countries, the PERFORM-P was developed. The PERFORM-P consists of a list of 61 items to be included in a forensic pathology report, which is accompanied by its Explanation and Elaboration (E&E) document. Discussion: To prepare forensic pathology (postmortem) reports that incorporate principles of evidence-based practice, internationally accepted recommendations might be helpful. The PERFORM-P identifies recommendations for necessary elements to include in a forensic pathology report. PERFORM-P can be applied to a wide range of matters requiring forensic pathological analysis, acceptable to forensic pathologists from a representative selection of jurisdictions and medico-legal systems. © 2021 The Authors |
Delphi study; Evidence-based practice; Forensic medicine; Forensic pathology; Reporting guides |
article; consensus; decision making; Delphi study; evidence based practice center; forensic pathology; human; pathologist; reliability; adult; consensus; evidence based practice; forensic pathology; international cooperation; middle aged; practice guideline; questionnaire; research; Adult; Consensus; Delphi Technique; Evidence-Based Practice; Forensic Pathology; Humans; Internationality; Middle Aged; Practice Guidelines as Topic; Research Report; Surveys and Questionnaires |
Elsevier Ireland Ltd |
03790738 |
|
34474199 |
Article |
Q1 |
912 |
5047 |
|
|
|
160 |
Yulian E.D., Siregar N.C., Bajuadji |
55983956600;6508087790;57318007000; |
Combination of Simvastatin and FAC Improves Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer |
2021 |
Cancer Research and Treatment |
53 |
4 |
|
1072 |
1083 |
|
2 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85111269220&doi=10.4143%2fcrt.2020.1024&partnerID=40&md5=fe14ed1b791ebc2592f487892c429602 |
Division of Surgical Oncology, Department of Surgery; Department of Pathology, Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Surgery, Koja General Hospital, Jakarta, Indonesia |
Yulian, E.D., Division of Surgical Oncology, Department of Surgery; Siregar, N.C., Department of Pathology, Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Bajuadji, Department of Surgery, Koja General Hospital, Jakarta, Indonesia |
Purpose The efficacy of neoadjuvant chemotherapy for locally advanced breast cancer (LABC) is limited due to drug resistance and cardiotoxic effects. Preclinical studies have shown that statin induces apoptosis and decreases breast cancer cell growth. This study aims to evaluate the role of statin in combination with fluorouracil, adriamycin, and cyclophosphamide (FAC) therapy in LABC patients. Materials and Methods We undertook a randomized, double-blinded, placebo-controlled trial in two centers of Indonesia. Patients were randomly assigned to FAC plus simvastatin (40 mg/day orally) or FAC plus placebo (40 mg/day) for 21 days. The FAC regimen was repeated every 3 weeks. We evaluated the clinical response, pathological response, and toxicities. Results The objective response rate (ORR) for FAC plus simvastatin was 90% (95% confidence interval [CI], 0.99 to 1.67) by per-protocol analysis. No complete responses (CR) were recorded, but there were 48 partial responses. No significant difference was observed between the two groups with the ORR (p=0.103). The pathological CR rate was 6.25% (2 in simvastatin group and 1 in placebo group). Adverse events in both arms were generally mild, mainly consisted of myotoxicity. Human epidermal growth factor receptor 2 (HER2) expression was a factor related to the success of therapeutic response (odds ratio, 4.2; 95% CI, 1.121 to 15.731; p=0.033). Conclusion This study suggests that simvastatin combined with FAC shows improvements in ORR and pathological response in patients with LABC. Although no statistically significant difference was documented, there was a trend for better activity and tolerability. The addition of 40 mg simvastatin may improve the efficacy of FAC in LABC patients with HER2 overexpression. Copyright 2021by theKoreanCancerAssociation |
Breast neoplasms; FAC; Neoadjuvant therapy; Simvastatin |
creatine kinase; cyclophosphamide; doxorubicin; epidermal growth factor receptor 2; fluorouracil; simvastatin; antineoplastic agent; cyclophosphamide; doxorubicin; epidermal growth factor receptor 2; ERBB2 protein, human; fluorouracil; simvastatin; adjuvant therapy; adult; advanced breast cancer; aged; alopecia; anemia; Article; blood toxicity; cancer combination chemotherapy; cancer surgery; clinical outcome; constipation; controlled study; creatine kinase blood level; diarrhea; double blind procedure; drug safety; drug tolerability; fatigue; female; gene overexpression; heart ejection fraction; histopathology; human; hypertransaminasemia; immunohistochemistry; Indonesia; invasive lobular breast carcinoma; leukopenia; lung metastasis; major clinical study; modified radical mastectomy; muc |
Korean Cancer Association |
15982998 |
|
33705623 |
Article |
Q1 |
1668 |
1870 |
|
|
|
163 |
Wahyuningsih R., Adawiyah R., Sjam R., Prihartono J., Ayu Tri Wulandari E., Rozaliyani A., Ronny R., Imran D., Tugiran M., Siagian F.E., Denning D.W. |
6507268400;57208658742;23398458200;6602605635;57224979940;57203065912;57224981604;57203976849;57218291154;57205685972;57223404509; |
Serious fungal disease incidence and prevalence in Indonesia |
2021 |
Mycoses |
64 |
10 |
|
1203 |
1212 |
|
1 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85108784112&doi=10.1111%2fmyc.13304&partnerID=40&md5=5f442b4c8248caad9f19e8d0d684dd18 |
Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Parasitology, Universitas Kristen Indonesia, School of Medicine, Jakarta, Indonesia; Department of Community Medicine Universitas Indonesia, Faculty of Medicine, Jakarta, Indonesia; Department of Dentistry, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Department of Neurology, Universitas Indonesia, Faculty of Medicine/Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Manchester Fungal Infection Group, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom |
Wahyuningsih, R., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Department of Parasitology, Universitas Kristen Indonesia, School of Medicine, Jakarta, Indonesia; Adawiyah, R., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Sjam, R., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Prihartono, J., Department of Community Medicine Universitas Indonesia, Faculty of Medicine, Jakarta, Indonesia; Ayu Tri Wulandari, E., Department of Dentistry, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Rozaliyani, A., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Ronny, R., Department of Parasitology, Universitas Kristen Indonesia, School of Medicine, Jakarta, Indonesia; Imran, D., Department of Neurology, Universitas Indonesia, Faculty of Medicine/Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Tugiran, M., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Siagian, F.E., Department of Parasitology, Universitas Kristen Indonesia, School of Medicine, Jakarta, Indonesia; Denning, D.W., Manchester Fungal Infection Group, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom |
Background: Indonesia is a tropical country, warm and humid, with numerous environmental fungi. Data on fungal disease burden help policymakers and clinicians. Objectives: We have estimated the incidence and prevalence of serious fungal diseases. Methods: We found all published and unpublished data and estimated the incidence and prevalence of fungal diseases based on populations at risk. HIV data were derived from UNAIDS (2017), pulmonary tuberculosis (PTB) data from 2013–2019, data on chronic pulmonary aspergillosis (CPA) were used to estimate CPA prevalence and likely deaths, COPD data from Hammond (2020), lung cancer incidence was from Globocan 2018, and fungal rhinosinusitis was estimated using community data from India. Results: Overall ~7.7 million Indonesians (2.89%) have a serious fungal infection each year. The annual incidence of cryptococcosis in AIDS was 7,540. Pneumocystis pneumonia incidence was estimated at 15,400 in HIV and an equal number in non-HIV patients. An estimated 1% and 0.2% of new AIDS patients have disseminated histoplasmosis or Talaromyces marneffei infection. The incidence of candidaemia is 26,710. The annual incidence of invasive aspergillosis was estimated at 49,500 and the prevalence of CPA is at 378,700 cases. Allergic bronchopulmonary aspergillosis prevalence in adults is estimated at 336,200, severe asthma with fungal sensitisation at 443,800, and fungal rhinosinusitis at 294,000. Recurrent vulvovaginal candidiasis is estimated at 5 million/year (15–50 years old). The incidence of fungal keratitis around 40,050. Tinea capitis prevalence in schoolchildren about 729,000. Conclusions: Indonesia has a high burden of fungal infections. © 2021 Wiley-VCH GmbH. |
aspergillosis; candidaemia; epidemiology |
acquired immune deficiency syndrome; adolescent; adult; AIDS patient; allergic bronchopulmonary aspergillosis; Article; atypical mycobacteriosis; candidemia; chronic infection; cryptococcosis; diabetic patient; disease association; disease burden; eye infection; female; fungal sinusitis; histoplasmosis; human; immunocompromised patient; incidence; Indonesia; invasive aspergillosis; keratomycosis; major clinical study; male; mycosis; nonhuman; Pneumocystis pneumonia; prevalence; recurrent infection; respiratory tract disease; severe asthma; skin infection; Talaromyces marneffei; tinea capitis; vagina candidiasis; acquired immune deficiency syndrome; AIDS related complex; candidemia; child; fungus; incidence; lung aspergillosis; middle aged; prevalence; young adult; mycosis; Acquired Immunod |
John Wiley and Sons Inc |
09337407 |
|
33971053 |
Article |
Q1 |
1130 |
3649 |
|
|
|
166 |
Sitohang I.B.S., Sirait S.A.P., Suryanegara J. |
56734569200;24482203600;57204535485; |
Microneedling in the treatment of atrophic scars: A systematic review of randomised controlled trials |
2021 |
International Wound Journal |
18 |
5 |
|
577 |
585 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100333569&doi=10.1111%2fiwj.13559&partnerID=40&md5=53a0daf4a5ed46e9fefa3f5918f68c9b |
Department of Dermatology and Venereology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia |
Sitohang, I.B.S., Department of Dermatology and Venereology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Sirait, S.A.P., Department of Dermatology and Venereology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Suryanegara, J., Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia |
To date, treatment of atrophic acne scars remains a therapeutic challenge for dermatologists, yet there is no standard option on the most effective treatment. Microneedling (MN) is a minimally invasive technology that involves repetitive skin puncture using sterile microneedles to disrupt dermal collagen that connects the scar tissue. Recent studies have demonstrated the potency of MN, such as dermaroller and fractionated microneedle radiofrequency, in the treatment of atrophic scars. The objective of this review is to evaluate systematically the current literature on MN for atrophic acne scars. A systematic search of literature was performed from PubMed, Medline, Cochrane Central, and Google Scholar databases for articles published during the last 20 years. Only randomised controlled trials (RCTs) with full-text version of the manuscript available were included in our study. Nine RCTs were included in this review. All treatment modalities demonstrated consistent results that MN was efficacious in treating atrophic acne scars as a monotherapy or in combination with other treatments. Moreover, no serious adverse effects were reported in all studies after MN treatment. MN is a well-tolerated and effective therapeutic modality in treating atrophic acne scars. Further research is required to validate the efficacy of MN with a larger sample size and lengthy follow-up. © 2021 The Authors. International Wound Journal published by Medicalhelplines.com Inc (3M) and John Wiley & Sons Ltd. |
atrophic acne scar; microneedling |
acne vulgaris; atrophy; complication; esthetic surgery; human; needle; pathology; randomized controlled trial (topic); scar; treatment outcome; Acne Vulgaris; Atrophy; Cicatrix; Cosmetic Techniques; Humans; Needles; Randomized Controlled Trials as Topic; Treatment Outcome |
John Wiley and Sons Inc |
17424801 |
|
33538106 |
Article |
Q1 |
867 |
5385 |
|
|
|
170 |
Nainggolan G., Soemarko D., Siregar P., Sutranto A.L., Bardosono S., Prijanti A.R., Aulia D. |
23498775400;57192889490;57205715021;57286411000;21933841000;57190863386;6602865986; |
Diagnostic role of urine specific gravity to detect kidney impairment on heat-exposed workers in a shoe factory in Indonesia: A cross-sectional study |
2021 |
BMJ Open |
11 |
9 |
e047328 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85116507527&doi=10.1136%2fbmjopen-2020-047328&partnerID=40&md5=b097275ffe1ee980cb242c3e4759fa0e |
Division of Nephrology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Division of Occupational Medicine, Department of Community Medicine, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Department of Nutrition, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Department of Biochemistry and Molecular Biology, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Department of Clinical Pathology, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia |
Nainggolan, G., Division of Nephrology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Soemarko, D., Division of Occupational Medicine, Department of Community Medicine, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Siregar, P., Division of Nephrology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Sutranto, A.L., Division of Nephrology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Bardosono, S., Department of Nutrition, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Prijanti, A.R., Department of Biochemistry and Molecular Biology, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Aulia, D., Department of Clinical Pathology, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia |
Objectives Globally, there are increasing cases of chronic kidney disease of unknown origin among heat-exposed workers. We aimed to see the kidney damages of indoor heat-exposed workers and whether urine specific gravity can predict any kidney damages. Design A cross-sectional study. Setting A shoe-making factory in West Java, Indonesia. Participants 119 subjects were included. Minimum total sample size was 62. Subjects were indoor heat-exposed workers who were exposed to occupational wet-bulb globe temperature (WBGT) of 28°C-30°C for 8 hours daily with 1 hour break, 5 days a week. The inclusion criterion was healthy subjects according to the result from annual medical check-up in 2019. The exclusion criteria were subjects who were taking vitamins and/or supplements that might cause disturbance in urine specific gravity and/or hydration status, pregnant and fasting. Primary and secondary outcome measures Area under the curve (AUC), sensitivity and specificity of urine specific gravity for the detection of urinary nephrin and urinary kidney injury molecule-1 (KIM-1) were analysed. Estimated glomerular filtration rate (eGFR) and quantitative albuminuria were also measured. Results WBGT in the work area of the subject was 28°C-30°C. There were 15 (12.6%) subjects who had eGFR <90 mL/min, but ≥60 mL/min. High serum vasopressin levels were found in 79 subjects with a mean of 6.54 (95% CI 5.94 to 7.14) ng/mL. Most subjects had nephrinuria (87.4%) with preserved renal function (87.4%). Several subjects had elevated urinary KIM-1 (10.9%) and albuminuria (7.6%). AUC of urine specific gravity for increased urinary nephrin was 81.7% (95% CI 68.8% to 94.6%) and statistically significant (p<0.001). Cut-off value of ≥1.018 for urine specific gravity has sensitivity of 71.2% and specificity of 80% for detecting elevation of urinary nephrin levels. Conclusion Urine specific gravity with a cut-off value of ≥1.018 could be used to detect nephrinuria among heat-exposed workers. © |
clinical chemistry; nephrology; occupational & industrial medicine |
albumin; hepatitis A virus cellular receptor 1; nephrin; vasopressin; adult; albumin blood level; albuminuria; Article; cross-sectional study; estimated glomerular filtration rate; factory worker; fasting; female; human; hydration status; Indonesia; kidney function; kidney injury; major clinical study; medical examination; nephrinuria; occupational exposure; pregnancy; proteinuria; relative density; sensitivity and specificity; shoe industry; thermal exposure; urine; urine level; urine sampling; vasopressin blood level; wet bulb globe temperature; wet bulb temperature; adverse event; chronic kidney failure; heat; heat injury; kidney; occupational exposure; relative density; Cross-Sectional Studies; Heat Stress Disorders; Hot Temperature; Humans; Indonesia; Kidney; Occupational Exposure; Re |
BMJ Publishing Group |
20446055 |
|
34588241 |
Article |
Q1 |
1132 |
3624 |
|
|
|
171 |
Pudjiadi A.H., Putri N.D., Sjakti H.A., Yanuarso P.B., Gunardi H., Roeslani R.D., Pasaribu A.D., Nurmalia L.D., Sambo C.M., Ugrasena I.D.G., Soeroso S., Firman A., Muryawan H., Setyanto D.B., Citraresmi E., Effendi J.A., Habibah L., Octaviantie P.D., Utami I.N.A., Prawira Y., Kaswandani N., Alam A., Kadafi K.T., Pulungan A.B. |
18435202300;57200573842;57195720458;57205428706;56510252700;57191512707;57287717900;57288262700;57287718000;57224730593;15133254800;57215582843;57287718100;57203009929;57224512641;57287899600;57287899700;57287718200;57287718300;55455747000;57195941745;57201672408;57211313656;57192905981; |
Pediatric COVID-19: Report From Indonesian Pediatric Society Data Registry |
2021 |
Frontiers in Pediatrics |
9 |
|
716898 |
|
|
|
1 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85116558206&doi=10.3389%2ffped.2021.716898&partnerID=40&md5=8c294f39457ac77d477f3bb1d2dd9eb4 |
The Indonesian Pediatric Society, Jakarta, Indonesia; Department of Pediatrics, Faculty of Medicine, Cipto Mangunkusumo National Central Hospital, Universitas Indonesia, Jakarta, Indonesia; Department of Pediatrics, Faculty of Medicine, Dr. Soetomo Hospital, Universitas Airlangga, Surabaya, Indonesia; Department of Pediatrics, Faculty of Medicine, Hasan Sadikin Hospital, Universitas Padjajaran, Bandung, Indonesia; Department of Pediatrics, Faculty of Medicine, Dr. Kariadi Hospital, Universitas Diponegoro, Semarang, Indonesia; Department of Pediatrics, Harapan Kita Women and Children Hospital, Jakarta, Indonesia; Department of Pediatrics, Fatmawati Hospital, Jakarta, Indonesia; Department of Pediatrics, Faculty of Medicine, Dr. Saiful Anwar Hospital, Universitas Brawijaya, Malang, Indonesia |
Pudjiadi, A.H., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Cipto Mangunkusumo National Central Hospital, Universitas Indonesia, Jakarta, Indonesia; Putri, N.D., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Cipto Mangunkusumo National Central Hospital, Universitas Indonesia, Jakarta, Indonesia; Sjakti, H.A., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Cipto Mangunkusumo National Central Hospital, Universitas Indonesia, Jakarta, Indonesia; Yanuarso, P.B., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Cipto Mangunkusumo National Central Hospital, Universitas Indonesia, Jakarta, Indonesia; Gunardi, H., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Cipto Mangunkusumo National Central Hospital, Universitas Indonesia, Jakarta, Indonesia; Roeslani, R.D., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Cipto Mangunkusumo National Central Hospital, Universitas Indonesia, Jakarta, Indonesia; Pasaribu, A.D., The Indonesian Pediatric Society, Jakarta, Indonesia; Nurmalia, L.D., The Indonesian Pediatric Society, Jakarta, Indonesia; Sambo, C.M., The Indonesian Pediatric Society, Jakarta, Indonesia; Ugrasena, I.D.G., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Dr. Soetomo Hospital, Universitas Airlangga, Surabaya, Indonesia; Soeroso, S., The Indonesian Pediatric Society, Jakarta, Indonesia; Firman, A., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Hasan Sadikin Hospital, Universitas Padjajaran, Bandung, Indonesia; Muryawan, H., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Dr. Kariadi Hospital, Universitas Diponegoro, Semarang, Indonesia; Setyanto, D.B., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Cipto Mangunkusumo National Central Hospital, Universitas Indonesia, Jakarta, Indonesia; Citraresmi, E., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Harapan Kita Women and Children Hospital, Jakarta, Indonesia; Effendi, J.A., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Fatmawati Hospital, Jakarta, Indonesia; Habibah, L., The Indonesian Pediatric Society, Jakarta, Indonesia; Octaviantie, P.D., Department of Pediatrics, Faculty of Medicine, Cipto Mangunkusumo National Central Hospital, Universitas Indonesia, Jakarta, Indonesia; Utami, I.N.A., The Indonesian Pediatric Society, Jakarta, Indonesia; Prawira, Y., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Cipto Mangunkusumo National Central Hospital, Universitas Indonesia, Jakarta, Indonesia; Kaswandani, N., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Cipto Mangunkusumo National Central Hospital, Universitas Indonesia, Jakarta, Indonesia; Alam, A., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Hasan Sadikin Hospital, Universitas Padjajaran, Bandung, Indonesia; Kadafi, K.T., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Dr. Saiful Anwar Hospital, Universitas Brawijaya, Malang, Indonesia; Pulungan, A.B., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Cipto Mangunkusumo National Central Hospital, Universitas Indonesia, Jakarta, Indonesia |
Background: Indonesia has a high number of COVID-19 cases and mortalities relative to not only among the Asia Pacific region but the world. Children were thought to be less affected by the virus compared to adults. Most of the public data reported combined data between adults and children. The Indonesian Pediatric Society (IPS) was involved in the COVID-19 response, especially in the area of child health. One of IPS's activities is collecting data registries from each of their chapters to provide a better understanding of COVID-19 in children. Objective: The objective of this study was to share the data of suspected and confirmed COVID-19 cases in children from IPS's COVID-19 data registry. Method: This is a retrospective study from the IPS's COVID-19 registry data. We collected the data of COVID-19 in children during March to December 2020 from each of the IPS chapters. We analyzed the prevalence, case fatality rate (CFR), age groups, diagnosis, and comorbidities of the children diagnosed with COVID-19. Result: As of December 21, 2020, there were 35,506 suspected cases of children with COVID-19. In total, there were 522 deaths, with a case fatality ratio (CFR) of 1.4. There were 37,706 confirmed cases with 175 fatalities (CFR 0.46). The highest mortality in confirmed COVID-19 cases was from children ages 10–18 years (42 out of 159 cases: 26%). The most common comorbidity and diagnosis found were malignancy (17.3%) and respiratory failure (54.5%). Conclusion: The CFR of confirmed COVID-19 cases in children in Indonesia is high and should be a major public concern. © Copyright © 2021 Pudjiadi, Putri, Sjakti, Yanuarso, Gunardi, Roeslani, Pasaribu, Nurmalia, Sambo, Ugrasena, Soeroso, Firman, Muryawan, Setyanto, Citraresmi, Effendi, Habibah, Octaviantie, Utami, Prawira, Kaswandani, Alam, Kadafi and Pulungan. |
children; comorbidities; COVID-19; Indonesia; mortality |
adolescent; adult; Article; case fatality rate; cause of death; child; comorbidity; coronavirus disease 2019; human; Indonesia; major clinical study; malignant neoplasm; medical society; mortality; pediatrics; prevalence; questionnaire; register; respiratory failure; retrospective study; sepsis; septic shock |
Frontiers Media S.A. |
22962360 |
|
|
Article |
Q1 |
960 |
4641 |
|
|
|
173 |
Forrat R., Dayan G.H., DiazGranados C.A., Bonaparte M., Laot T., Capeding M.R., Sanchez L., Coronel D.L., Reynales H., Chansinghakul D., Hadinegoro S.R.S., Perroud A.P., Frago C., Zambrano B., Machabert T., Wu Y., Luedtke A., Price B., Vigne C., Haney O., Savarino S.J., Bouckenooghe A., Noriega F. |
36339272700;6701860993;56721307400;56614799700;24471016000;6602161242;57201082261;56418742600;55343075300;29067671300;56893685800;57198777256;56255310300;7801355579;57201364463;57215829074;54395741500;57002517700;57192890936;57215866119;57220410062;18233281300;7005980306; |
Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America |
2021 |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |
73 |
6 |
|
1003 |
1012 |
|
1 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85116958578&doi=10.1093%2fcid%2fciab288&partnerID=40&md5=cceec1a946e6b236b138dcb4bb663855 |
Clinical Sciences, Sanofi Pasteur, Marcy l'Etoile, France; Clinical Sciences Sanofi PasteurPA, United States; Translation Sciences and Biomarkers, Sanofi PasteurPA, United States; Global Clinical Science, Sanofi Pasteur, Taguig City, Philippines; Research Institute for Tropical Medicine, Medical Department, Muntinlupa, Philippines; Clinical Sciences, Sanofi PasteurMexico City, Mexico; Centro de Atencion e Investigación Médica, Bogotá, Colombia; Research & Development, Sanofi PasteurBangkok, Thailand; Cipto Mangunkusumo Hospital, University of IndonesiaJakarta, Indonesia; Clinical Sciences, Sanofi Pasteur, São Paulo, Brazil; Clinical Sciences, Sanofi Pasteur, Singapore; Clinical Sciences, Sanofi Pasteur, Uruguay; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States; Global Pharmacovigilance, Sanofi PasteurPA, United States |
Forrat, R., Clinical Sciences, Sanofi Pasteur, Marcy l'Etoile, France; Dayan, G.H., Clinical Sciences Sanofi PasteurPA, United States; DiazGranados, C.A., Clinical Sciences Sanofi PasteurPA, United States; Bonaparte, M., Translation Sciences and Biomarkers, Sanofi PasteurPA, United States; Laot, T., Global Clinical Science, Sanofi Pasteur, Taguig City, Philippines; Capeding, M.R., Research Institute for Tropical Medicine, Medical Department, Muntinlupa, Philippines; Sanchez, L., Global Clinical Science, Sanofi Pasteur, Taguig City, Philippines; Coronel, D.L., Clinical Sciences, Sanofi PasteurMexico City, Mexico; Reynales, H., Centro de Atencion e Investigación Médica, Bogotá, Colombia; Chansinghakul, D., Research & Development, Sanofi PasteurBangkok, Thailand; Hadinegoro, S.R.S., Cipto Mangunkusumo Hospital, University of IndonesiaJakarta, Indonesia; Perroud, A.P., Clinical Sciences, Sanofi Pasteur, São Paulo, Brazil; Frago, C., Clinical Sciences, Sanofi Pasteur, Singapore; Zambrano, B., Clinical Sciences, Sanofi Pasteur, Uruguay; Machabert, T., Clinical Sciences, Sanofi Pasteur, Marcy l'Etoile, France; Wu, Y., Clinical Sciences Sanofi PasteurPA, United States; Luedtke, A., Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States; Price, B., Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States; Vigne, C., Clinical Sciences, Sanofi Pasteur, Marcy l'Etoile, France; Haney, O., Global Pharmacovigilance, Sanofi PasteurPA, United States; Savarino, S.J., Translation Sciences and Biomarkers, Sanofi PasteurPA, United States; Bouckenooghe, A., Clinical Sciences, Sanofi Pasteur, São Paulo, Brazil; Noriega, F., Clinical Sciences Sanofi PasteurPA, United States |
BACKGROUND: CYD-TDV, a live, attenuated, tetravalent dengue vaccine, has been approved for the prevention of symptomatic dengue in previously dengue exposed individuals. This post hoc analysis assessed hospitalized and severe virologically confirmed dengue (VCD) over the complete 6-year follow-up of 3 CYD-TDV efficacy studies (CYD14, CYD15, and CYD23/CYD57). METHODS: The main outcomes were hazard ratios (HRs) for hospitalized or severe VCD by baseline dengue serostatus, focusing on those who were seropositive, and by age at immunization (<9 years/≥9 years). Baseline dengue serostatus was measured or inferred using several methods. Hospitalized VCD cases were characterized in terms of clinical signs and symptoms and wild-type viremia level. Antibody persistence was assessed up to 5 years after the last injection. RESULTS: In those aged ≥9 years and baseline seropositive, CYD-TDV protected against hospitalized and severe VCD over 6 years compared to placebo (HR [95% confidence interval] multiple imputation from month 0 method, .19 [.12-.30] and .15 [.06-.39]; other methods were consistent). Vaccine protection was observed over the different study periods, being highest during the first 2 years. Evidence for a decreased risk of hospitalized and severe VCD was also observed in seropositive participants aged 6-8 years. Clinical signs and symptoms, and quantified dengue viremia from participants with hospitalized VCD were comparable between groups. CONCLUSIONS: CYD-TDV demonstrated robust protection against hospitalized and severe VCD over the entire 6-year follow-up in participants who were seropositive and ≥9 years old. Protection was also observed in seropositive 6-8 year-olds. Clinical Trials Registration: NCT00842530, NCT01983553, NCT01373281, NCT01374516. © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. |
CYD-TDV; dengue; serostatus; VCD |
dengue vaccine; live vaccine; vaccine; virus antibody; Asia; child; controlled study; dengue; Dengue virus; follow up; human; randomized controlled trial; severe dengue; South and Central America; Antibodies, Viral; Asia; Child; Dengue; Dengue Vaccines; Dengue Virus; Follow-Up Studies; Humans; Latin America; Severe Dengue; Vaccines, Attenuated; Vaccines, Combined |
NLM (Medline) |
15376591 |
|
33822015 |
Article |
Q1 |
3440 |
518 |
|
|
|
174 |
Ambari A.M., Setianto B., Santoso A., Radi B., Dwiputra B., Susilowati E., Tulrahmi F., Wind A., Cramer M.J.M., Doevendans P. |
57189576921;57192893995;36905206100;6603494019;57195383994;57200092387;57210209635;57265425700;7102305152;7004918581; |
Randomised controlled trial into the role of ramipril in fibrosis reduction in rheumatic heart disease: The RamiRHeD trial protocol |
2021 |
BMJ Open |
11 |
9 |
e048016 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85115217044&doi=10.1136%2fbmjopen-2020-048016&partnerID=40&md5=37438fc881ccc33516a8361ba43e3971 |
Department of Cardiovascular Prevention and Rehabilitation, National Cardiovascular Center Harapan Kita, West Jakarta Jakarta, Indonesia; Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, West Jakarta Jakarta, Indonesia; Research Assistant of Department of Cardiovascular Prevention and Rehabilitation, National Cardiovascular Center Harapan Kita, West Jakarta Jakarta, Indonesia; Department of Cardiology, University Medical Centre Utrecht, Utrecht, Netherlands; Central Military Hospital, Netherlands Heart Institute, Utrecht, Netherlands |
Ambari, A.M., Department of Cardiovascular Prevention and Rehabilitation, National Cardiovascular Center Harapan Kita, West Jakarta Jakarta, Indonesia, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, West Jakarta Jakarta, Indonesia; Setianto, B., Department of Cardiovascular Prevention and Rehabilitation, National Cardiovascular Center Harapan Kita, West Jakarta Jakarta, Indonesia, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, West Jakarta Jakarta, Indonesia; Santoso, A., Department of Cardiovascular Prevention and Rehabilitation, National Cardiovascular Center Harapan Kita, West Jakarta Jakarta, Indonesia, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, West Jakarta Jakarta, Indonesia; Radi, B., Department of Cardiovascular Prevention and Rehabilitation, National Cardiovascular Center Harapan Kita, West Jakarta Jakarta, Indonesia, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, West Jakarta Jakarta, Indonesia; Dwiputra, B., Department of Cardiovascular Prevention and Rehabilitation, National Cardiovascular Center Harapan Kita, West Jakarta Jakarta, Indonesia, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, West Jakarta Jakarta, Indonesia; Susilowati, E., Research Assistant of Department of Cardiovascular Prevention and Rehabilitation, National Cardiovascular Center Harapan Kita, West Jakarta Jakarta, Indonesia; Tulrahmi, F., Research Assistant of Department of Cardiovascular Prevention and Rehabilitation, National Cardiovascular Center Harapan Kita, West Jakarta Jakarta, Indonesia; Wind, A., Department of Cardiology, University Medical Centre Utrecht, Utrecht, Netherlands; Cramer, M.J.M., Department of Cardiology, University Medical Centre Utrecht, Utrecht, Netherlands; Doevendans, P., Department of Cardiology, University Medical Centre Utrecht, Utrecht, Netherlands, Central Military Hospital, Netherlands Heart Institute, Utrecht, Netherlands |
Introduction Rheumatic heart disease (RHD) is a major burden in developing countries and accounts for 80% of all people living with the disease, where it causes most cardiovascular morbidity and mortality in children and young adults. Chronic inflammation and fibrosis of heart valve tissue due to chronic inflammation in RHD will cause calcification and thickening of the impacted heart valves, especially the mitral valve. This fibrogenesis is enhanced by the production of angiotensin II by increased transforming growth factor β expression and later by the binding of interleukin-33, which is known to have antihypertrophic and antifibrotic effects, to soluble sST2. sST2 binding to this non-natural ligand worsens fibrosis. Therefore, we hypothesise that ACE inhibitors (ACEIs) would improve rheumatic mitral valve stenosis. Methods and analysis This is a single-centre, double-blind, placebo-controlled, randomised clinical trial with a pre-post test design. Patients with rheumatic mitral stenosis and valve dysfunction will be planned for cardiac valve replacement operation and will be given ramipril 5 mg or placebo for a minimum of 12 weeks before the surgery. The expression of ST2 in the mitral valve is considered to be representative of cardiac fibrosis. Mitral valve tissue will be stained by immunohistochemistry to ST2. Plasma ST2 will be measured by ELISA. This study is conducted in the Department of Cardiology and Vascular Medicine, Universitas Indonesia, National Cardiac Center Harapan Kita Hospital, Jakarta, Indonesia, starting on 27 June 2019. Ethics and dissemination The performance and dissemination of this study were approved by the ethics committee of National Cardiovascular Center Harapan Kita with ethical code LB.02.01/VII/286/KEP.009/2018. Trial registration number NCT03991910. © 2021 BMJ Publishing Group. All rights reserved. |
cardiology; cardiothoracic surgery; valvular heart disease |
interleukin 1 receptor like 1 protein; placebo; ramipril; ramipril; adult; Article; clinical trial protocol; controlled study; double blind procedure; enzyme linked immunosorbent assay; female; heart muscle fibrosis; human; human tissue; immunohistochemistry; Indonesia; male; mitral valve stenosis; pretest posttest design; protein blood level; protein expression; randomized controlled trial; rheumatic heart disease; child; fibrosis; heart surgery; mitral valve stenosis; randomized controlled trial (topic); young adult; Cardiac Surgical Procedures; Child; Fibrosis; Humans; Mitral Valve Stenosis; Ramipril; Randomized Controlled Trials as Topic; Rheumatic Heart Disease; Young Adult |
BMJ Publishing Group |
20446055 |
|
34518254 |
Article |
Q1 |
1132 |
3624 |
|
|
